Biopharmaceutical Indications and Targets: Past, Present, and Future. | CPhI North America

CPhI North America is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

 

View, browse and sort the ever-growing list of sessions by pass type, track, and format. With this Session Scheduler, you can build your schedule in advance and access it during the show via export or with the Mobile App, once live. Sessions do fill up and seating is first come, first serve, so arrive early to sessions that you would like to attend.

Biopharmaceutical Indications and Targets: Past, Present, and Future.

Dawn Ecker (Consultant, BioProcess Technology Consultants)

Location: bioLIVE Theater

Date: Tuesday, April 30

Time: 1:20pm - 1:40pm

Track: The BPI Theater

Vault Recording: TBD

Since the approval of Humulin in 1982 and OKT3 in 1986, the recombinant biopharmaceutical landscape has changed significantly. Leveraging the bioTRAK database, the shifts in indications and targets for approved biopharmaceuticals over four decades will be profiled. Looking forward, the current pipeline of recombinant products in development will be analyzed to project what changes might be in store for biopharma’s future.